Nano X Imaging Ltd (NNOX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $25.36M
Last updated: Nov 17, 2026 at 11:06 AM ET
Nano X Imaging Ltd (NNOX) Earnings: Report Dates and Results
Nano X Imaging (NNOX) is expected to report earnings on Nov 25, 2026. In the quarter ended Jun 30, 2026, Nano X Imaging reported EPS of -$0.79, below the -$0.12 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NNOX has an expected report date of Nov 25, 2026.
NNOX Earnings Call
The latest NNOX earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 25 quarters below that had an estimate, NNOX beat 11, missed 11 and matched 3. Revenue for the quarter ended Jun 30, 2026 was $4.16M, up 36.8% from $3.04M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.79 | -$0.12 | -$0.12 - -$0.12 | -558.33% | Miss | N/A | 1 | 1 up, 0 down | Jul 20, 2026 | $4.16M |
| Mar 31, 2026 | -$0.20 | -$0.14 | -$0.14 - -$0.14 | -42.86% | Miss | N/A | 1 | 0 up, 0 down | Apr 20, 2026 | $4.31M |
| Dec 31, 2025 | -$0.17 | -$0.15 | -$0.15 - -$0.15 | -13.33% | Miss | N/A | 2 | 1 up, 0 down | Dec 31, 2025 | $3.72M |
| Sep 30, 2025 | -$0.15 | -$0.17 | -$0.21 - -$0.14 | +11.76% | Beat | N/A | 2 | 0 up, 1 down | Nov 20, 2025 | $3.45M |
| Jun 30, 2025 | -$0.17 | -$0.15 | -$0.16 - -$0.14 | -13.33% | Miss | N/A | 2 | 1 up, 0 down | Aug 12, 2025 | $3.04M |
| Mar 31, 2025 | -$0.15 | -$0.15 | -$0.15 - -$0.15 | 0.00% | In line | N/A | 2 | 1 up, 0 down | May 22, 2025 | $2.81M |
| Dec 31, 2024 | -$0.17 | -$0.15 | -$0.15 - -$0.15 | -13.33% | Miss | N/A | 1 | 1 up, 0 down | Mar 31, 2025 | $3.00M |
| Sep 30, 2024 | -$0.15 | -$0.15 | -$0.15 - -$0.15 | 0.00% | In line | N/A | 1 | 1 up, 0 down | Nov 21, 2024 | $3.03M |
| Jun 30, 2024 | -$0.14 | -$0.15 | N/A | +6.67% | Beat | N/A | 3 | 0 up, 0 down | Aug 20, 2024 | $2.70M |
| Mar 31, 2024 | -$0.21 | -$0.26 | -$0.28 - -$0.24 | +19.23% | Beat | N/A | 2 | 0 up, 0 down | May 28, 2024 | $2.55M |
| Dec 31, 2023 | -$0.18 | -$0.30 | -$0.38 - -$0.24 | +40.00% | Beat | N/A | 3 | 0 up, 0 down | Mar 14, 2024 | $2.40M |
| Sep 30, 2023 | -$0.37 | -$0.30 | -$0.35 - -$0.26 | -23.33% | Miss | N/A | 3 | 0 up, 0 down | Nov 28, 2023 | $2.48M |
| Jun 30, 2023 | -$0.31 | -$0.26 | -$0.30 - -$0.23 | -19.23% | Miss | N/A | 2 | 0 up, 0 down | Aug 17, 2023 | $2.58M |
| Mar 31, 2023 | -$0.21 | -$0.34 | -$0.35 - -$0.33 | +38.24% | Beat | N/A | 2 | 0 up, 0 down | May 22, 2023 | $2.45M |
| Dec 31, 2022 | -$0.86 | -$0.43 | -$0.57 - -$0.36 | -100.00% | Miss | N/A | 3 | 0 up, 0 down | Mar 9, 2023 | $2.45M |
| Sep 30, 2022 | -$0.37 | -$0.42 | -$0.49 - -$0.37 | +11.90% | Beat | N/A | 3 | 0 up, 0 down | Nov 10, 2022 | $2.44M |
| Jun 30, 2022 | -$0.38 | -$0.25 | -$0.30 - -$0.16 | -52.00% | Miss | N/A | 3 | 0 up, 0 down | Aug 16, 2022 | $2.20M |
| Mar 31, 2022 | -$0.41 | -$0.22 | -$0.29 - -$0.22 | -86.36% | Miss | N/A | 2 | 0 up, 0 down | May 19, 2022 | $1.81M |
| Dec 31, 2021 | -$0.45 | -$0.33 | -$0.42 - -$0.25 | -36.36% | Miss | N/A | 3 | 0 up, 0 down | Mar 31, 2022 | $2.20M |
| Sep 30, 2021 | -$0.28 | -$0.28 | -$0.30 - -$0.27 | 0.00% | In line | N/A | 3 | N/A | Nov 17, 2021 | N/A |
| Jun 30, 2021 | -$0.18 | -$0.20 | N/A | +10.00% | Beat | N/A | 4 | N/A | Aug 10, 2021 | N/A |
| Mar 31, 2021 | -$0.15 | -$0.27 | -$0.27 - -$0.24 | +44.44% | Beat | N/A | 2 | N/A | May 11, 2021 | N/A |
| Dec 31, 2020 | -$0.18 | -$0.20 | -$0.27 - -$0.13 | +10.00% | Beat | N/A | 2 | N/A | Mar 2, 2021 | N/A |
| Sep 30, 2020 | -$0.13 | -$0.27 | -$0.33 - -$0.13 | +51.85% | Beat | N/A | 2 | N/A | Nov 9, 2020 | N/A |
| Jun 30, 2020 | -$0.02 | -$0.23 | N/A | +91.30% | Beat | N/A | N/A | N/A | Jul 31, 2020 | N/A |
| Dec 31, 2019 | -$0.51 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jan 14, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.64, after -$0.67 the year before. It was -$0.51 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.64 | N/A |
| Dec 31, 2024 | -$0.67 | N/A |
| Dec 31, 2023 | -$1.07 | N/A |
| Dec 31, 2022 | -$2.02 | N/A |
| Dec 31, 2021 | -$1.06 | N/A |
| Dec 31, 2020 | -$0.33 | N/A |
| Dec 31, 2019 | -$0.51 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 5,600 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 5,635 | 6 | |
| 2026Q1 | Mar 31, 2026 | 3,262 | 6 | |
| 2025Q4 | Dec 31, 2025 | 6,026 | 6 | |
| 2025Q3 | Sep 30, 2025 | 5,818 | 7 | |
| 2025Q2 | Jun 30, 2025 | 5,569 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,608 | 7 | |
| 2024Q4 | Dec 31, 2024 | 6,620 | 9 | |
| 2024Q3 | Sep 30, 2024 | 5,793 | 7 |
2026Q2 Earnings Call
Opening remarks
Mike Cavanaugh Investor Relations Good morning. Welcome to the Nano-X Imaging first quarter 2026 investor call. Earlier today, Nano-X Imaging Ltd. released financial results for the quarter ending March 31, 2026. The release is currently available on the investors section of the company's website. With me today are Erez Meltzer, Chief Executive Officer and Acting Chairman. Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements regarding the company's financial results, research and development, manufacturing, commercialization activities, regulatory process, and clinical activities, and other matters. These statements are subject to risks, uncertainties and assumptions that are based on management's current expectations as of today and may not be updated in the future. These statements should not be relied upon as representing the company's views as of any subsequent date. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. We will also refer to certain non-GAAP financial measures to provide additional information to investors. A reconciliation of the non-GAAP to GAAP measures is provided with our press release, with the primary differences being non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, and non-GAAP gross loss per share. With that, I'd now like to turn the call over to Erez Meltzer.
Erez Meltzer Chief Executive Officer and Acting Chairman Good morning. Thank you for joining us today for the Nano-X Imaging first quarter 2026 financial results conference call. I'm pleased to report that, as previously indicated, we are beginning to see early signs of revenue from Nanox.ARC. We are seeing momentum across multiple fronts, from record deployments to expanding partnerships supporting our technology and business model. We have worked diligently over the past two years to place a new technology in the medical imaging market. This process takes significant time and effort. We have learned many lessons during this time. We are using those lessons learned to help reshape our go-to-market strategy. Specifically, we have made various adaptations to our company strategy and operating model to better position us for long-term success. Changing behaviors is a long process. We need to educate customers not only on the medical utility of the Nanox systems, but also demonstrate why using them will benefit their practices financially. Here are some of the changes we have implemented based on lessons learned. First, we have restructured our U.S. commercial model to emphasize partnerships. This multi-channel approach supplements our direct sales efforts and provides broader market coverage more efficiently.
Frequently Asked Questions About NNOX
When is Nano X Imaging's next earnings date?
Nano X Imaging's next earnings report is expected for Nov 25, 2026.
Did NNOX beat earnings estimates last quarter?
No. Nano X Imaging reported EPS of -$0.79 for the quarter ended Jun 30, 2026, below the -$0.12 estimate by 558.33%.
What EPS do analysts expect from NNOX next quarter?
The consensus EPS estimate for Nano X Imaging for the quarter ended Sep 30, 2026 is -$0.14 from 1 analyst, with estimates from -$0.14 to -$0.14.
How often does NNOX beat earnings estimates?
Nano X Imaging beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -78.68%.
NNOX pages: Overview, Earnings, Forecast, Financials, Competitors